Sean P. Lyden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sean P. Lyden has a total of 439 co-authors. Here are the top co-authors by number of shared publications:
Francis J. Caputo
Department of Vascular Surgery, Heart, Thoracic, Vascular Institute, Cleveland Clinic, Cleveland, OH
12 shared publicationsLevester Kirksey
Department of Vascular Surgery, Heart Vascular and Thoracic Institute, Cleveland Clinic, OH, USA
9 shared publicationsJarrad W. Rowse
Department of Vascular Surgery, Miller Family Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH
8 shared publicationsDaniel G. Clair
Palmetto Health USC Medical Group
7 shared publicationsJon G. Quatromoni
Department of Vascular Surgery, Miller Family Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH
7 shared publications- Ahmed A. Sorour
Department of Vascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio
5 shared publications
Latest Publications
- Open Access
- 9 July 2026
- Published by Wolters Kluwer Health in Kidney360
Vascular Access-Related Heart Failure
Arteriovenous access-related heart failure (ARHF) is a critical yet underrecognized complication in ESKD patients on hemodialysis. Heart failure is highly prevalent among patients with ESKD and is often characterized as uremic cardiomyopathy. In this setting, the increased hemodynamic load imposed by a functioning hemodialysis access circuit can further aggravate the underlying myocardial pathology, potentially precipitating high-output heart failure. Vascular access accounts for 23% of high-output heart failure cases, carrying a 58% five-year mortality rate. Despite its prevalence, ARHF remains underdiagnosed and mismanaged due to a lack of established societal guidelines. This narrative review aims to delineate the complex pathophysiology of ARHF, highlight current diagnostic challenges, identify existing gaps in evidence, and suggest potential methods to enhance its management. Hemodynamic changes are investigated, including increased cardiac output, cardiac remodeling, pulmonary hypertension, and arterial stiffening, alongside non-hemodynamic factors. Diagnostic modalities, including history and physical exam, laboratory cardiac biomarkers, transthoracic echocardiography, vascular duplex ultrasound, magnetic resonance imaging and right heart catheterization are discussed. Management strategies, encompassing preoperative prevention and risk stratification, medical therapies, surgical interventions (e.g., banding), and surveillance protocols, are also outlined. This comprehensive review addresses current evidence gaps and provides clinical guidance to improve ARHF recognition, diagnosis, and management.
- 9 July 2026
- Published by Wolters Kluwer Health in Kidney360
Open AccessVascular Access-Related Heart Failure
Arteriovenous access-related heart failure (ARHF) is a critical yet underrecognized complication in ESKD patients on hemodialysis. Heart failure is highly prevalent among patients with ESKD and is often characterized as uremic cardiomyopathy. In this setting, the increased hemodynamic load imposed by a functioning hemodialysis access circuit can further aggravate the underlying myocardial pathology, potentially precipitating high-output heart failure. Vascular access accounts for 23% of high-output heart failure cases, carrying a 58% five-year mortality rate. Despite its prevalence, ARHF remains underdiagnosed and mismanaged due to a lack of established societal guidelines. This narrative review aims to delineate the complex pathophysiology of ARHF, highlight current diagnostic challenges, identify existing gaps in evidence, and suggest potential methods to enhance its management. Hemodynamic changes are investigated, including increased cardiac output, cardiac remodeling, pulmonary hypertension, and arterial stiffening, alongside non-hemodynamic factors. Diagnostic modalities, including history and physical exam, laboratory cardiac biomarkers, transthoracic echocardiography, vascular duplex ultrasound, magnetic resonance imaging and right heart catheterization are discussed. Management strategies, encompassing preoperative prevention and risk stratification, medical therapies, surgical interventions (e.g., banding), and surveillance protocols, are also outlined. This comprehensive review addresses current evidence gaps and provides clinical guidance to improve ARHF recognition, diagnosis, and management.
- Open Access
- 23 June 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (8)
Durability of the DETOUR System for Long and Complex Femoral-Popliteal Lesions: 3-Year Results From the DETOUR2 Trial
- 23 June 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (8)
Open AccessDurability of the DETOUR System for Long and Complex Femoral-Popliteal Lesions: 3-Year Results From the DETOUR2 Trial
- 16 June 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (10) , 108910
Comparison of Three-Year U.S. Payer Costs for Endovascular Treatment Options to Treat Femoropopliteal Artery Disease
- 16 June 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (10) , 108910
Comparison of Three-Year U.S. Payer Costs for Endovascular Treatment Options to Treat Femoropopliteal Artery Disease
- 4 June 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (1) , 1-3
Rethinking endoleaks: is it time to change the name?
- 4 June 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (1) , 1-3
Rethinking endoleaks: is it time to change the name?
- 2 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (22) , 1761-1780
Standardized End Point Definitions for Clinical Trials in Thoracic Aortic Repair: A Consensus Report From the ARCH–Academic Research Consortium
Innovation in the treatment of ascending aorta and arch pathology with novel catheter-based and hybrid procedures has driven the need for a strategy to guide their safe application. The ARCH-ARC (Aortic Arch Academic Research Consortium) was established to pragmatically develop consistent clinical end points and to standardize definitions for use in studies of these new technologies. The ARCH-ARC team, consisting of independent international specialists in cardiac surgery, vascular surgery, vascular medicine, cardiology, neurology, radiology, and clinical trials, along with US Food and Drug Administration, industry, and contract research organization representatives, held virtual meetings from 2021 to 2025. Consensus was used to identify appropriate clinical end points and to standardize definitions of end points for endovascular, hybrid, and open surgical procedures in clinical trials in the ascending aorta and arch. Drawing on previous ARC work in cardiac, neurological, renal, and bleeding end points, the ARCH-ARC focused on definitions and end points related to aortic arch–specific anatomy, pathology, and procedures and clinical, device, and imaging. The adoption of the ARCH-ARC consensus definitions and end points will provide a template for consistent adjudication and event reporting and facilitate comparisons of clinical research studies involving devices for ascending aorta and arch pathology.
- 2 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (22) , 1761-1780
Standardized End Point Definitions for Clinical Trials in Thoracic Aortic Repair: A Consensus Report From the ARCH–Academic Research Consortium
Innovation in the treatment of ascending aorta and arch pathology with novel catheter-based and hybrid procedures has driven the need for a strategy to guide their safe application. The ARCH-ARC (Aortic Arch Academic Research Consortium) was established to pragmatically develop consistent clinical end points and to standardize definitions for use in studies of these new technologies. The ARCH-ARC team, consisting of independent international specialists in cardiac surgery, vascular surgery, vascular medicine, cardiology, neurology, radiology, and clinical trials, along with US Food and Drug Administration, industry, and contract research organization representatives, held virtual meetings from 2021 to 2025. Consensus was used to identify appropriate clinical end points and to standardize definitions of end points for endovascular, hybrid, and open surgical procedures in clinical trials in the ascending aorta and arch. Drawing on previous ARC work in cardiac, neurological, renal, and bleeding end points, the ARCH-ARC focused on definitions and end points related to aortic arch–specific anatomy, pathology, and procedures and clinical, device, and imaging. The adoption of the ARCH-ARC consensus definitions and end points will provide a template for consistent adjudication and event reporting and facilitate comparisons of clinical research studies involving devices for ascending aorta and arch pathology.
- Open Access
- 2 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e047145
Value‐Based Medicine in the Management of Abdominal Aortic Aneurysms
The implementation of value‐based medicine reflects a transformation from volume incentivized care to a quality‐of‐care directed reimbursement model. Value‐based medicine aims to concurrently improve health care quality and control growing health care expenditures by aligning evidence‐based and patient‐centered interventions with sustainable resource use. We apply a value‐based medicine framework to abdominal aortic aneurysm care delivery, highlighting opportunities to improve patient outcomes, optimize resource allocation, and reduce health care expenditures across the continuum of disease management. A comprehensive literature review was conducted, evaluating recent clinical guidelines, economic analyses, and real‐world practice data on abdominal aortic aneurysm management, including screening, surveillance, timing of intervention, modality selection (endovascular aneurysm repair versus open surgical repair), and follow‐up strategies. Contemporary real‐world published practice patterns reveal wide variation in screening uptake, surveillance intensity, repair criteria thresholds, procedure and device selection, and post‐endovascular aneurysm repair imaging, producing inconsistent outcomes and inefficient spending. Endovascular aneurysm repair predominates in elective abdominal aortic aneurysm repair because of lower perioperative morbidity and shorter length of stay; however, downstream costs from surveillance, endoleak management, and reinterventions may erode its initial economic advantage over open surgical repair. Key value drivers include risk‐aligned screening, standardized surveillance anchored to anatomy and device risk, judicious use of advanced imaging, optimized perioperative pathways, and careful device selection. Savings opportunities include predictive analytics to individualize surveillance, deescalation of routine computed tomography after documented sac shrinkage, smoking cessation, medical optimization, and structured shared decision‐making aligned with life expectancy and patient preferences. Integrating value‐based medicine principles into abdominal aortic aneurysm care through regional centers of excellence, bundled reimbursement models, transparent cost structures, and surveillance strategies may offer a pragmatic roadmap to achieve safer, economically sustainable, and patient‐centered management, ultimately advancing both clinical outcomes and cost efficiency.
- 2 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e047145
Open AccessValue‐Based Medicine in the Management of Abdominal Aortic Aneurysms
The implementation of value‐based medicine reflects a transformation from volume incentivized care to a quality‐of‐care directed reimbursement model. Value‐based medicine aims to concurrently improve health care quality and control growing health care expenditures by aligning evidence‐based and patient‐centered interventions with sustainable resource use. We apply a value‐based medicine framework to abdominal aortic aneurysm care delivery, highlighting opportunities to improve patient outcomes, optimize resource allocation, and reduce health care expenditures across the continuum of disease management. A comprehensive literature review was conducted, evaluating recent clinical guidelines, economic analyses, and real‐world practice data on abdominal aortic aneurysm management, including screening, surveillance, timing of intervention, modality selection (endovascular aneurysm repair versus open surgical repair), and follow‐up strategies. Contemporary real‐world published practice patterns reveal wide variation in screening uptake, surveillance intensity, repair criteria thresholds, procedure and device selection, and post‐endovascular aneurysm repair imaging, producing inconsistent outcomes and inefficient spending. Endovascular aneurysm repair predominates in elective abdominal aortic aneurysm repair because of lower perioperative morbidity and shorter length of stay; however, downstream costs from surveillance, endoleak management, and reinterventions may erode its initial economic advantage over open surgical repair. Key value drivers include risk‐aligned screening, standardized surveillance anchored to anatomy and device risk, judicious use of advanced imaging, optimized perioperative pathways, and careful device selection. Savings opportunities include predictive analytics to individualize surveillance, deescalation of routine computed tomography after documented sac shrinkage, smoking cessation, medical optimization, and structured shared decision‐making aligned with life expectancy and patient preferences. Integrating value‐based medicine principles into abdominal aortic aneurysm care through regional centers of excellence, bundled reimbursement models, transparent cost structures, and surveillance strategies may offer a pragmatic roadmap to achieve safer, economically sustainable, and patient‐centered management, ultimately advancing both clinical outcomes and cost efficiency.
- Open Access
- 26 May 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (4) , 951-960.e3
30-Day Outcomes Following Transcarotid Artery Revascularization with Integrated Embolic Protection (TCAR-IEP) The PERFORMANCE III Study
- 26 May 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (4) , 951-960.e3
Open Access30-Day Outcomes Following Transcarotid Artery Revascularization with Integrated Embolic Protection (TCAR-IEP) The PERFORMANCE III Study
- Open Access
- 15 May 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (3) , 661-670.e23
Contemporary systematic review and meta-analysis of outcomes associated with femoropopliteal above-the-knee nonautologous surgical bypass
- 15 May 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (3) , 661-670.e23
Open AccessContemporary systematic review and meta-analysis of outcomes associated with femoropopliteal above-the-knee nonautologous surgical bypass
- 22 April 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (2) , 363-370
Evaluation of sac volume regression after aortic aneurysm sac embolization with shape memory polymer plugs in patients undergoing endovascular aneurysm repair
- 22 April 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (2) , 363-370
Evaluation of sac volume regression after aortic aneurysm sac embolization with shape memory polymer plugs in patients undergoing endovascular aneurysm repair